Researchers from King's College London and UCB Pharma Inc. recently reported preclinical data on the effects of an anti-mouse neonatal Fc receptor (FcRn) antibody, UCB-4470, on circulating antiphospholipid (aPL) and aPL-induced thrombus formation in mice.
Brain insulin signaling is known to control peripheral energy metabolism and regulation of mood and cognition. Dysregulation in this signaling has been tied to brain pathological disorders such as Alzheimer’s disease (AD). Previous findings have reported a strong connection between type 2 diabetes (T2D) and AD, suggesting insulin resistance as a potential risk factor for AD pathology and other forms of dementia.
Investigators at the University of Bristol and Biognos AB have identified a structural feature that distinguished the deadly coronavirus strains from harmless, common cold-causing variants. The findings, which were published in the Nov. 23, 2022, issue of Science Advances, could form the basis of universal COVID antivirals, putting an end to the endless race to deal with new variants that has so far been a necessity.
The researchers showed that the same pocket, a binding site for linoleic acid (LA), was present in all variants of concern (VOCs) that have emerged since 2020. “Intriguingly, all SARS-CoV-2 VOCs stringently maintain this pocket, notably including Omicron, which accumulated a wide range of mutations in [the spike protein] elsewhere, suggesting that the pocket provides a selective advantage for the virus,” they wrote in their paper.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) ligand binding moiety covalently bound to a bromodomain-containing protein 4 (BRD4; HUNK1)-targeting moiety through a linker.
Genescience Pharmaceuticals Co. Ltd. has divulged indoline-containing spiro derivatives acting as growth hormone secretagogue receptor (GHSR) agonists reported to be useful for the treatment of growth hormone deficiency.
Bionova Pharmaceuticals Ltd. has identified heteroaromatic carboxamide compounds acting as Bruton tyrosine kinase (BTK) and BTK (C481S mutant) inhibitors reported to be useful for the treatment of asthma, cancer, graft-vs.-host disease, inflammatory bowel disease, psoriasis, thrombotic thrombocytopenic purpura, rheumatoid arthritis and autoimmune thyroiditis, among others.
Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have identified heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Shanghai Shyndec Pharmaceutical Co. Ltd. have detailed the discovery of novel selective serotonin reuptake inhibitor (SSRI)/5-HT1A dual targeting compounds as potential antidepressant candidates.
Investigators from Immunos Therapeutics AG aimed to develop novel anticancer therapies by using a reverse rational approach from HLA class I molecules with the aim to induce autoimmunity, and they identified HLA-B*57 as a well-known genetic factor associated with superior control of viral infections through processes not linked with peptide presentation.
RSS
